X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA WOCKHARDT LTD. ALEMBIC PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 28.4 -18.7 - View Chart
P/BV x 6.5 3.1 211.4% View Chart
Dividend Yield % 0.7 1.1 67.6%  

Financials

 ALEMBIC PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
WOCKHARDT LTD.
Mar-17
ALEMBIC PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs7921,129 70.1%   
Low Rs443627 70.7%   
Sales per share (Unadj.) Rs167.0363.1 46.0%  
Earnings per share (Unadj.) Rs38.2-20.4 -186.6%  
Cash flow per share (Unadj.) Rs42.0-7.0 -602.0%  
Dividends per share (Unadj.) Rs4.0010.00 40.0%  
Dividend yield (eoy) %0.61.1 56.9%  
Book value per share (Unadj.) Rs84.9301.8 28.1%  
Shares outstanding (eoy) m188.52110.55 170.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.72.4 152.9%   
Avg P/E ratio x16.2-42.9 -37.7%  
P/CF ratio (eoy) x14.7-125.9 -11.7%  
Price / Book Value ratio x7.32.9 250.0%  
Dividend payout %10.5-48.9 -21.4%   
Avg Mkt Cap Rs m116,38397,063 119.9%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m4,2149,665 43.6%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m31,48740,146 78.4%  
Other income Rs m551,143 4.8%   
Total revenues Rs m31,54241,289 76.4%   
Gross profit Rs m10,060128 7,859.2%  
Depreciation Rs m7221,489 48.5%   
Interest Rs m372,253 1.6%   
Profit before tax Rs m9,356-2,472 -378.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160-211 -1,023.3%   
Profit after tax Rs m7,194-2,260 -318.3%  
Gross profit margin %31.90.3 10,020.5%  
Effective tax rate %23.18.5 270.3%   
Net profit margin %22.8-5.6 -405.8%  
BALANCE SHEET DATA
Current assets Rs m15,06646,160 32.6%   
Current liabilities Rs m7,67419,258 39.8%   
Net working cap to sales %23.567.0 35.0%  
Current ratio x2.02.4 81.9%  
Inventory Days Days67101 66.5%  
Debtors Days Days4194 43.2%  
Net fixed assets Rs m8,23740,165 20.5%   
Share capital Rs m377553 68.2%   
"Free" reserves Rs m15,41632,814 47.0%   
Net worth Rs m16,00533,367 48.0%   
Long term debt Rs m031,903 0.0%   
Total assets Rs m24,59489,687 27.4%  
Interest coverage x255.2-0.1 -262,786.6%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.30.4 286.0%   
Return on assets %29.40 -342,465.7%  
Return on equity %44.9-6.8 -663.5%  
Return on capital %58.7-0.3 -17,503.5%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,8119,121 195.3%   
Fx outflow Rs m5,3182,133 249.3%   
Net fx Rs m12,4936,988 178.8%   
CASH FLOW
From Operations Rs m9,304-2,695 -345.3%  
From Investments Rs m-3,105-6,863 45.2%  
From Financial Activity Rs m-1,95912,545 -15.6%  
Net Cashflow Rs m4,2403,010 140.8%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 2.3 126.1%  
FIIs % 9.1 7.7 118.2%  
ADR/GDR % 0.0 0.1 -  
Free float % 13.9 15.4 90.3%  
Shareholders   49,328 67,757 72.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS